The next phase of Napa’s decades-long flood-control project, involving work on floodwalls north of the Oxbow Bypass, is one step closer to reality.

In a phase 3 trial, Axpaxli, a tyrosine kinase inhibitor, achieved its superiority primary endpoint vs. aflibercept for the ...

Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 1:00 PM ESTCompany ParticipantsJoshua Bleharski - ...

Researchers evaluated whether hormonal biomarkers in women with relapsing-remitting MS varied significantly when accounting for menstrual phase or menopausal status.

Viking Therapeutics (VKTX +4.90%) is aiming to join one of the biggest growth industries of the times: the weight loss drug ...

WICHITA, KS, UNITED STATES, February 15, 2026 /EINPresswire.com/ -- Nitride Global, Inc. (NGI), a global leader in ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Armed group Hezbollah rejected on Tuesday the Lebanese government's decision to grant the army at least four months to ...

In practical terms, the control plane shows up across everyday platforms: Parents using banking apps to restrict a child’s ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...